Skip to content

Welcome

Celebrating Over 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

AAOA Member Benefits

  • Up to 60% discount for CME programs and free Annual Meeting. All AAOA’s CME programs meet ABOTOHNS Continuing Certification.
  • AAOA US ENT Affinity program, where AAOA members can gain savings on antigen, allergy supplies, and any of the other 5 service lines US ENT offers. For more email info@usentpartners.com.
  • Tools and resources to comply with US General Chapter 797 and practice management tools.
  • Advocacy support.
  • And much more! Learn More

ADVOCACY UPDATES

Upcoming Dates

04/01/24: Fellow Exam Application Deadline
Learn more

06/01/24: Research Grant Cycle
Learn more

06/25/24: Membership Application Deadline to be eligible for AAOA Member rate for the 2024 Basic Course

08/02/24: Scientific Abstract Submission Deadline
Learn more

12/01/24: Research Grant Cycle
Learn more

EDUCATION

AAOA Advanced Course

The recorded course content is available until April 30, 2024. This year’s Advanced Course featured Laryngology and Skull Base Surgery with Nausheen Jamal, MD and Garret Choby, MD as featured faculty.

RESIDENTS

For information about Resident membership, opportunities, DosedDaily, research grants, and other resources. Learn More

IFAR

Available Now

aaoaf-ifar

IFAR Impact Factor: 2.454

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2024 AAOA Advanced Course in Allergy & Immunology - Hybrid
On-Demand Content Access Deadline:
April 30, 2024
Learn More and Register

2024 AAOA Basic Course in Allergy & Immunology - Hybrid
July 25-27, 2024
The Diplomat, Hollywood, Florida
Learn More and Register

2024 AAOA Annual Meeting - Hybrid
November 8-10, 2024
Four Seasons Hotel Las Vegas
Learn More 

USP 797 Online Module
Learn More and Register

AAOA Educational Stacks
Next Availability - April 1, 2024

News and Updates

FDA Approval of First and Only Digital Inhaler with Built-In Sensors

The Food and Drug Administration (FDA) has approved ProAir Digihaler (albuterol sulfate) inhalation powder for…

Read more

From the AAOA President, Matthew Ryan, MD

...the AAOA continues to be the organization that Otolaryngologists look to for up-to-date education and information on the…

Read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PARTNER RESOURCE CENTER

AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>

PATIENT CORNER

Practice Resources

Ingestion Challenge Testing

peanuts-2163043_640

Ingestion Challenge Testing Update 2013

Previously ingestion challenge testing for food, drugs or other substance was reported under Code 95075. That code has been deleted and effective January 1, 2013 is replaced by two new codes 95076 and 95079.

Code 95076 is defined as Ingestion challenge test (sequential and incremental ingestion of test items, e.g., food, drug or other substance); initial 120 minutes of testing.

Code 95079 is an add on code always reported with Code 95076 and is defined as each additional minutes of testing (list separately in addition to code for primary procedure.

As an example for the use of the new codes for drug allergy testing, consider a common protocol for penicillin allergy testing.  An initial single prick test is performed with each of the following: histamine, saline, benzylpenicilloyl polylysine (Pre-Pen), and penicillin G.

If these tests are “negative”, intradermal tests are then performed in the following manner: one intradermal application of a saline control, and two intradermal injections each for benzylpenicilloyl polylysine and penicillin G.

If the intradermal tests are “negative”, then on oral challenge with a penicillin product is given, and the patient is observed for one hour. The physician should bill for 9 units of 95018 (4 prick and 5 intradermal tests), and 1 unit of 95076 for the oral challenge test.

A Member Benefit

Allergy and Rhinology Journal (IFAR)

The International Forum of Allergy & Rhinology (IFAR) is the official journal of the AAOA and the American Rhinologic Society (ARS). Published monthly by John Wiley & Sons, Inc., IFAR provides a forum for clinical researchers, basic scientists, clinicians, and others to publish original research and explore controversies in the medical and surgical treatment of patients with otolaryngic allergy, rhinologic, and skull base conditions.

President Mims Message

April 2017

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices. Read More

News

New Articles from IFAR

Safety of long-term Intranasal Budesonide

The aim of this study was to determine the impact of long-term topical budesonide treatment via the mucosal atomization device (MAD) on the hypothalamic-pituitary-adrenal axis (HPAA) and intraocular pressure (IOP).. Read More

Medical therapy for Chronic Rhino-sinusitis

The indications for surgical management of chronic rhinosinusitis (CRS) in patients with cystic fibrosis (CF) are poorly defined..
Read More

New Blog Posts

Posts from AAOA Leaders

Allergies, not just for summer anymore. Read More

How to treat allergies at home.
Read More

Back To Top